Key points New evidence has led to a change in the way that some patients with amyotrophic lateral sclerosis (ALS) are classified and treated. Based on the findings of a landmark trial,[1][1] the drug ...
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback